Irofulven
- CAS NO.:920014-72-8
- Empirical Formula: C49H68N18O9S2
- Molecular Weight: 1117.32
- MDL number: MFCD30532719
- Update Date: 2024-03-27 11:49:37
What is Irofulven?
Absorption
Setmelanotide has a Tmax of 8 hours.
Toxicity
Data regarding overdoses of setmelanotide are not readily available. In the event of an overdose, patients should be treated with symptomatic and supportive care.
Indications
Setmelanotide is indicated for chronic weight management in patients 6 years and older with obesity due to pro-opiomelanocortin (POMC) deficiency, proprotein subtilisin/kexin type 1 (PCSK1) deficiency, or leptin receptor (LEPR) deficiency as determined by an approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance. These conditions affect the MC4R signalling pathway.
Setmelanotide is also indicated for chronic weight management in patients 6 years and older with obesity due to Bardet-Biedl syndrome.
The drug is not reported to be effective in patients with POMC, PCSK1, or LEPR variants classified as benign or likely benign, as well as other types of obesity not listed above.
Background
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other earlier treatments for these patients included gastric bypass surgery. Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week.
Imcivree was granted EMA orphan designation on November 19, 2018 and FDA approval on November 25, 2020. On May 4, 2023, it was approved by Health Canada.
Pharmacokinetics
Setmelanotide agonizes MC4R, downstream of multiple potential genetic deficiencies, to induce a feeling of satiety for chronic weight management. It has a moderate duration of action as it is given daily. Patients should be counselled regarding the risk of disturbances in sexual arousal, depression and suicidal ideation, and darkening of skin pigmentation. Exercise caution in neonates and low birth weight infants, as they may experience serious adverse effects due to benzyl alcohol.
Metabolism
Setmelanotide is expected to be metabolized to small peptides and amino acids.
Properties of Irofulven
Density | 1.54±0.1 g/cm3(Predicted) |
pka | 12.82±0.70(Predicted) |
Safety information for Irofulven
Computed Descriptors for Irofulven
New Products
6-Bromo 2-Iodo Indole Fosfomycin EP impurity D Rimegepant Impurity 3 Ivermectin EP Impurity B 2,2-diethoxyethanethioamide Tubulysin M Tubulysin I Tubulysin D (2S,4R)-4-amino-2-methyl-5-phenylpentanoic acid hydrochloride Imeglimin Hydrochloride IH 2-(1-(Mercaptomethyl) cyclopropyl) acetonitrile (1R,2S)-2-(3,4-Difluorophenyl)cyclopropanamine Fuel shell 2-[[(3aR,4S,6R,6aS)-6-Aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol ethanedioate 2-[2-[3(S)-3[2-(7-chloro-2-quinolinyl) ethenyl] phenyl-3- hydroxyl propyl] phenyl]-2-propanol 2-Chloro-3-(chloromethyl)pyridine 4-Bromo-N,N-bis(4-iodophenyl)aniline 5-Aminophthalazine 2-(2,4-Dibutoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 2-(4-Bromopyridin-2-yl)acetonitrile 3,6-Bis(4-iodophenyl)-2,5-dihydropyrrolo[3,4-c]pyrrole-1,4-dione 2-chloro-(4-Trifluoromethyl) benzyl bromide (-)-1-Phenyl ethane sulfonic acid 6-HydroxyisoquinolineRelated products of tetrahydrofuran
You may like
-
3,6-Bis(4-iodophenyl)-2,5-dihydropyrrolo[3,4-c]pyrrole-1,4-dioneView Details
952145-70-9 -
452-58-4View Details
452-58-4 -
1262243-12-8View Details
1262243-12-8 -
65195-56-4View Details
65195-56-4 -
Rimegepant Impurity 3View Details
-
Sidchem 730View Details
-
Sidchem BT 20View Details
-
1572177-89-9View Details
1572177-89-9